159 related articles for article (PubMed ID: 38206552)
1. Novel alternative tools for metastatic pheochromocytomas/paragangliomas prediction.
Cui Y; Zhou Y; Gao Y; Ma X; Wang Y; Zhang X; Zhou T; Chen S; Lu L; Zhang Y; Chang X; Tong A; Li Y
J Endocrinol Invest; 2024 May; 47(5):1191-1203. PubMed ID: 38206552
[TBL] [Abstract][Full Text] [Related]
2. Development and internal validation of a novel predictive model for
Zhou Y; Gao Y; Ma X; Li T; Cui Y; Wang Y; Li M; Zhang D; Tong A
Front Endocrinol (Lausanne); 2023; 14():1285631. PubMed ID: 38179299
[TBL] [Abstract][Full Text] [Related]
3. [Metastatic risk factors in pheochromocytoma/paraganglioma].
Rebrova DV; Loginova OI; Vorobyev SL; Vorokhobina NV; Kozorezova ES; Indeykin FA; Savelyeva TV; Sleptsov IV; Chernikov RA; Fedorov EA; Semenov AA; Chinchuk IK; Shikhmagomedov SS; Alekseev MA; Krasnov LM; Rusakov VF
Probl Endokrinol (Mosk); 2023 Oct; 70(2):37-45. PubMed ID: 38796759
[TBL] [Abstract][Full Text] [Related]
4. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma.
Job S; Draskovic I; Burnichon N; Buffet A; Cros J; Lépine C; Venisse A; Robidel E; Verkarre V; Meatchi T; Sibony M; Amar L; Bertherat J; de Reyniès A; Londoño-Vallejo A; Favier J; Castro-Vega LJ; Gimenez-Roqueplo AP
Clin Cancer Res; 2019 Jan; 25(2):760-770. PubMed ID: 30301828
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a novel nomogram predicting pseudohypoxia type pheochromocytomas and paragangliomas.
Wang Y; Liu L; Chen D; Pang Y; Xu X; Liu J; Li M; Guan X
J Endocrinol Invest; 2023 Jul; 46(7):1361-1371. PubMed ID: 36508127
[TBL] [Abstract][Full Text] [Related]
6. A nomogram for predicting the presence of germline mutations in pheochromocytomas and paragangliomas.
Su TW; Zhong X; Ye L; Song W; Jiang L; Xie J; Jiang Y; Zhou W; Zhang C; Wu L; Ning G; Wang W
Endocrine; 2019 Dec; 66(3):666-672. PubMed ID: 31606865
[TBL] [Abstract][Full Text] [Related]
7. Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.
Zhong X; Ye L; Su T; Xie J; Zhou W; Jiang Y; Jiang L; Ning G; Wang W
Clin Endocrinol (Oxf); 2017 Aug; 87(2):127-135. PubMed ID: 28429830
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas.
Zhou Y; Cui Y; Zhang D; Tong A
J Clin Endocrinol Metab; 2023 Feb; 108(3):755-766. PubMed ID: 36383456
[TBL] [Abstract][Full Text] [Related]
11. Clinical differences between small and large pheochromocytomas and paragangliomas.
Zhao L; Li Z; Meng X; Fan H; Zhang Z; Zhang Z; Liu Y; Zhou X; Zhu H
Front Endocrinol (Lausanne); 2023; 14():1087506. PubMed ID: 36967797
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
[TBL] [Abstract][Full Text] [Related]
13. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
14. Early distinction of lymph node metastasis in patients with soft tissue sarcoma and individualized survival prediction using the online available nomograms: A population-based analysis.
Tong Y; Pi Y; Cui Y; Jiang L; Gong Y; Zhao D
Front Oncol; 2022; 12():959804. PubMed ID: 36568161
[TBL] [Abstract][Full Text] [Related]
15. SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis.
Su T; Yang Y; Jiang L; Xie J; Zhong X; Wu L; Jiang Y; Zhang C; Zhou W; Ye L; Ning G; Wang W
Front Endocrinol (Lausanne); 2023; 14():1121397. PubMed ID: 37008946
[TBL] [Abstract][Full Text] [Related]
16. [Development and validation of a prognostic model for patients with sepsis in intensive care unit].
Jiang Z; Wang H; Wang S; Guan C; Qu Y
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Aug; 35(8):800-806. PubMed ID: 37593856
[TBL] [Abstract][Full Text] [Related]
17. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma.
Xu A; Chu X; Zhang S; Zheng J; Shi D; Lv S; Li F; Weng X
BMC Cancer; 2022 Aug; 22(1):872. PubMed ID: 35945526
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and a predictive nomogram for hemodynamic instability during adrenalectomy for large pheochromocytomas and paragangliomas: A retrospective cohort study.
Li S; Li Z; Zheng J; Chen X
Eur J Surg Oncol; 2023 Oct; 49(10):106964. PubMed ID: 37369608
[TBL] [Abstract][Full Text] [Related]
20. Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer.
Wu Q; Sun MS; Liu YH; Ye JM; Xu L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12333-12353. PubMed ID: 37432458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
